Who are anti-thymocyte globulin (ATG)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, ELRANATAMAB, Elrexfio, Talvey, Epkinly, Bcmaxcd3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-thymocyte-globulin-atg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

anti-thymocyte globulin (ATG) — Competitive Intelligence Brief

anti-thymocyte globulin (ATG) (anti-thymocyte globulin (ATG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant CD3 Immunology Biologic Live · refreshed every 30 min

Target snapshot

anti-thymocyte globulin (ATG) (anti-thymocyte globulin (ATG)) — Memorial Sloan Kettering Cancer Center. Anti-thymocyte globulin (ATG) works by binding to and depleting T-lymphocytes, which are a type of immune cell.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
anti-thymocyte globulin (ATG) TARGET	anti-thymocyte globulin (ATG)	Memorial Sloan Kettering Cancer Center	phase 3	Immunosuppressant	CD3
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
ELRANATAMAB	ELRANATAMAB		marketed		BCMA, CD3	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
Bcmaxcd3	TECLISTAMAB	Johnson & Johnson	marketed		CD3, BCMA	2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
I.M. Sechenov First Moscow State Medical University · 1 drug in this class
Kenya Medical Research Institute · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
RWTH Aachen University · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). anti-thymocyte globulin (ATG) — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-thymocyte-globulin-atg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab